Last reviewed · How we verify
Ulunar
Ulunar, marketed by Fundacio Privada Mon Clinic Barcelona, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current marketed status, providing a stable revenue stream for the company. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Ulunar |
|---|---|
| Also known as | LABA/LAMA |
| Sponsor | Fundacio Privada Mon Clinic Barcelona |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ANTES B+ Clinical Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |